

2018

# ANNUAL REPORT



## 2018 MID-COLUMBIA MEDICAL CENTER CANCER COMMITTEE ANNUAL REPORT

[www.mcmc.net](http://www.mcmc.net)

**CELILO  
CANCER  
CENTER AT  
MID-COLUMBIA  
MEDICAL CENTER**

**Celilo Cancer Center** is one of just 16 Commission on Cancer (CoC) accredited centers in Oregon. At Celilo Cancer Center we strive to deliver cutting-edge oncology care to the communities in The Gorge and have been doing so for nearly two decades.

As part of our continued commitment, we annually conduct at least two studies of quality and institute at least two quality improvements. These studies are focused on improving patient outcomes as well as assessing past treatment of our patients compared to evidence-based standards of care.

In 2018, our Cancer Committee, a committed group of physicians, administrators, nurses and other allied healthcare professionals, reviewed our care of glioblastoma, a rare and highly aggressive form of brain tumor. According to an article from Journal of Neuro-Oncology (2017)\*, patients newly diagnosed with glioblastoma benefit from care at a hospital that treats a high number of patients with brain tumors. In a chart review of 10 randomly selected patients with glioblastoma treated at Celilo Cancer Center from 2014 through 2017, with the exception of one patient who declined workup and treatment, all patients were treated appropriately per National Comprehensive Cancer Network (NCCN) guidelines with 100% compliance, as determined by Dr. Stelzer, our radiation oncologist and cancer liaison officer of cancer committee.

### 2018 MCMC CANCER COMMITTEE

<b>Lynne Allen</b> NP, AOCNP, ACHPN	<b>Gary Gingrich</b> MD	<b>Paula Lee-Valkov</b> MD
<b>Rebecca Attwood</b> CTR	<b>Kim Harley</b> RN, BSN	<b>Caitlin McCarthy</b> MD
<b>Andrew Boyer</b> MD	<b>Hahn Huang</b> MD	<b>Symantha McClennan</b> Data Management
<b>Amanda Cummings</b> Pharm D	<b>Eric Holeman</b> Pharm D	<b>Kerry Proctor</b> MD
<b>Tracy Dugick</b> RD	<b>Melodi Johnson</b> RN, BSN, OCN	<b>Clyde Sanda</b> Spiritual Care
<b>Steve Fu</b> MD, PhD, Chairman	<b>Keith Stelzer</b> MD, PhD Cancer Liaison Physician	<b>Tamara Telles</b> American Cancer Society <b>Donald Wenzler</b> CNO
	<b>Pamela Whiteman</b> CSW-A	



CELILO CANCER CENTER

Two quality studies were completed in 2018. Both centered on assessing and evaluating an existing process and procedure for the purpose of improving patient health and well-being.

Medical Oncology representatives to the Cancer Committee brought concerns about frequency of Celilo Cancer Center patient visits to MCMC's Emergency Department (ED). This study had the two-fold goal of improving our patients' health and comfort while reducing visits to the Emergency Department. All ED admissions were studied February-August 2018. The following trends were identified: Pain, though not necessarily cancer-related pain, was the most common reason for an ED Admit; 204 medical oncology patients went to the ED, 54 of them within 30 days of their most recent cancer treatment, though reason for ED admit was not necessarily cancer-related. 73 patients called the on-call oncologist and of that 73, nine subsequently presented to the ED. We noticed a direct correlation between talking with the on-call provider and not presenting to the ED.

We determined that in most cases, if the patient talks with the on-call provider prior to presenting to the ED, the patient's need is met and they do not present to the ED. We focused on reducing ED visits by encouraging patients to call the on-call provider prior to presenting to the ED for non-life-threatening healthcare questions and concerns, which also saves them time and money. To facilitate this process for patients, three inch by four inch refrigerator magnets will be provided to each patient at their first nurse visit. The magnets will include contact information, including after-hours contact information, for Celilo Cancer Center. The patient will be encouraged to call the on-call provider as their first step. Patients will also be invited to include the on-call contact information in their cell phone contact list, assistance will be provided by Celilo staff as needed.

One study was a retrospective chart review of patients at Celilo Cancer Center receiving cisplatin-based regimens, a commonly used chemotherapy for treatment of many types of cancers. Under the direction of Eric Holeman, Pharm D, data was compiled from October 2017 through August 2018 to analyze toxicities, discontinuations, and dose reductions related to this type of regimen.

A total of 15 patient charts were evaluated. Charts were reviewed and data collected for: diagnosis, chemotherapy regimen, initial dose, number of doses

scheduled, number of doses administered, discontinuation reason, number of dose reductions, baseline kidney function, as well as during and after treatment, pre and post hydration volume, diuretic use, and magnesium supplementation. It was noted that during this period of time, we may have had a higher rate of nephrotoxicity (toxicity to kidneys) as determined based on the Common Terminology Criteria for Adverse Events (CTCAE).

We therefore implemented changes in our protocol to aggressively hydrate patients, add magnesium supplementation, and add mannitol for diuresis. The pharmacist or doctor shall assess patients for additional risk factors and consider more aggressive preventative measures or adjustment of cisplatin dose as needed.

This year, we also had our every three-year survey from National Accreditation Program for Breast Centers (NAPBC) for re-accreditation of The Breast Center at MCMC. For a small, rural medical center such as MCMC, to have both a CoC-accredited cancer center as well as a NAPBC-accredited breast center in itself is a remarkable achievement. Our breast cancer center was initially certified in 2009 as one of the first breast centers in the west coast. This reaffirms the fact that our breast cancer care meets or exceeds national standards. We can proudly say that you do not have to travel far to receive the best breast cancer care, it is right here for you!

Cancer immunotherapy has dramatically changed our approach to cancer and has revolutionized cancer care. Celilo Cancer Center takes pride in offering our patients cutting-edge cancer care with a variety of immunotherapies involving many type of cancers such as lung cancer, kidney cancer, and melanoma. In addition to immunotherapy, targeted therapies are also being used almost routinely in many type of cancers such as breast and prostate cancer. It offers more specific and effective cancer treatment while avoiding many of the traditional side-effects of chemotherapy. With the advance of science, we increasingly send tumors for gene analysis in order to determine the best possible treatment. We also actively review patients for appropriate clinical trials and refer to OHSU Knight Cancer Institute and Seattle Cancer Care Alliance as applicable.

We are in an exciting era in terms of cancer treatment, it offers our patients more hope than ever.

\* <https://today.uic.edu/treatment-nonexistent-for-some-glioblastoma-patients>